Targeting novel and established therapies for non-small cell lung cancer
- 18 May 2007
- journal article
- review article
- Published by Elsevier in Cancer Letters
- Vol. 250 (1) , 9-16
- https://doi.org/10.1016/j.canlet.2006.09.001
Abstract
No abstract availableKeywords
This publication has 47 references indexed in Scilit:
- Cutaneous Adverse Effects With HER1/EGFR-Targeted Agents: Is There a Silver Lining?Journal of Clinical Oncology, 2005
- Practical Management of Patients With Non–Small-Cell Lung Cancer Treated With GefitinibJournal of Clinical Oncology, 2005
- Determinants of Tumor Response and Survival With Erlotinib in Patients With Non—Small-Cell Lung CancerJournal of Clinical Oncology, 2004
- Efficacy of Gefitinib, an Inhibitor of the Epidermal Growth Factor Receptor Tyrosine Kinase, in Symptomatic Patients With Non–Small Cell Lung CancerJAMA, 2003
- Multi-Institutional Randomized Phase II Trial of Gefitinib for Previously Treated Patients With Advanced Non–Small-Cell Lung CancerJournal of Clinical Oncology, 2003
- The druggable genomeNature Reviews Drug Discovery, 2002
- Comparison of Four Chemotherapy Regimens for Advanced Non–Small-Cell Lung CancerNew England Journal of Medicine, 2002
- Cell Signaling by Receptor Tyrosine KinasesPublished by Elsevier ,2000
- The Hallmarks of CancerCell, 2000
- Chemotherapy for non-small cell lung cancerBMJ, 1995